Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pharvaris N.V.

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris to Host Virtual Investor Event on October 23, 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Presents Data at the Bradykinin Symposium 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Announces Extraordinary Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris to Present at the WSAAI Annual Meeting 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris to Present at the GA²LEN UCARE Conference 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.